FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Aklog Lishan
  2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [PAVM]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chairman and CEO
(Last)
(First)
(Middle)
ONE GRAND CENTRAL PLACE, SUITE 4600
3. Date of Earliest Transaction (Month/Day/Year)
08/29/2017
(Street)

NEW YORK, NY 10165
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/29/2017   P   1,412 A (1) 60,289 D  
Common Stock 08/30/2017   P   300 A (2) 60,589 D  
Common Stock 08/31/2017   P   1,600 A (3) 62,189 D  
Common Stock 09/01/2017   P   300 A (4) 62,489 D  
Common Stock               285 I By daughter
Common Stock               300 I By son
Common Stock               5,713,879 I By HCFP/Capital Partners III LLC (8)
Common Stock               2,520,532 I By Pavilion Venture Partners LLC (9)
Common Stock               87,020 I By HCFP Inc. (10)
Common Stock               125,000 I By HCFP/Capital Partners IIIB LLC (11)
Common Stock               20,000 I By HCFP/AG LLC (12)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants $ 5 08/29/2017   P   1,200   10/28/2016 01/29/2022 Common Stock 1,200 (5) 46,500 D  
Warrants $ 5 08/30/2017   P   200   10/28/2016 01/29/2022 Common Stock 200 $ 1.22 46,700 D  
Warrants $ 5 08/31/2017   P   1,700   10/28/2016 01/29/2022 Common Stock 1,700 (6) 48,400 D  
Warrants $ 5 09/01/2017   P   200   10/28/2016 01/29/2022 Common Stock 200 (7) 48,600 D  
Warrants $ 5             10/28/2016 01/29/2022 Common Stock 5,713,879   5,713,879 I By HCFP/Capital Partners III LLC (8)
Warrants $ 5             10/28/2016 01/29/2022 Common Stock 2,220,532   2,220,532 I By Pavilion Venture Partners LLC (9)
Warrants $ 5             10/28/2016 01/29/2022 Common Stock 387,020   387,020 I By HCFP Inc. (10)
Warrants $ 5             10/28/2016 01/29/2022 Common Stock 125,000   125,000 I By HCFP/Capital Partners IIIB LLC (11)
Warrants $ 5             10/28/2016 01/29/2022 Common Stock 20,000   2,000 I By HCFP/AG LLC (12)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Aklog Lishan
ONE GRAND CENTRAL PLACE
SUITE 4600
NEW YORK, NY 10165
  X   X   Chairman and CEO  
HCFP/Capital Partners III LLC
ONE GRAND CENTRAL PLACE
SUITE 4600
NEW YORK, NY 10165
    X    
Pavilion Venture Partners LLC
ONE GRAND CENTRAL PLACE
SUITE 4600
NEW YORK, NY 10165
    X    

Signatures

 /s/ Dr. Lishan Aklog   09/05/2017
**Signature of Reporting Person Date

 /s/ Dr. Lishan Aklog, as manager of HCFP/Capital Partners III LLC   09/05/2017
**Signature of Reporting Person Date

 /s/ Dr. Lishan Aklog, as manager of Pavilion Venture Partners LLC   09/05/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares were purchased at a weighted average price of approximately $4.19770538 per share. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
(2) The shares were purchased at a weighted average price of approximately $4.19666667 per share. These shares were purchased in multiple transactions at prices ranging from $4.19 to $4.20, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
(3) The shares were purchased at a weighted average price of approximately $4.2725 per share. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.40, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
(4) The shares were purchased at a weighted average price of approximately $4.45666667 per share. These shares were purchased in multiple transactions at prices ranging from $4.39 to $4.50, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.
(5) The warrants were purchased at a weighted average price of approximately $1.4875 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.18 to $2.24, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4.
(6) The warrants were purchased at a weighted average price of approximately $1.0375 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.01 to $1.09, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4.
(7) The warrants were purchased at a weighted average price of approximately $1.19 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.18 to $1.20, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4.
(8) Dr. Aklog is a member and a co-manager of HCFP/Capital Partners III LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
(9) Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
(10) Dr. Aklog is a controlling shareholder of HCFP Inc., and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.
(11) Dr. Aklog is a member and a co-manager of the entity that acts as sole manager of HCFP/Capital Partners IIIB LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.
(12) Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.